Lluis Castells

Lluis Castells

Auto-generated profile, based on publicly available information

Lluis Castells

Liver Unit, Department of Medicine Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona Barcelona Spain

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 1999 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
PSPau Sort
Pau Sort
MNMiquel Navasa
Miquel Navasa
VAVicente Arroyo
Vicente Arroyo
XAXavier Aldeguer
Xavier Aldeguer
RPRamon Planas
Ramon Planas
JRJoan Rodés
Joan Rodés
In patients with cirrhosis and spontaneous bacterial peritonitis, renal function frequently becomes impaired. This impairment is probably related to a reduction in effective arterial blood volume and is associated with a high mortality rate. We conducted a study to determine whether plasma volume expansion with intravenous albumin prevents renal impairment and reduces mortality in these patients. We randomly assigned 126 patients with cirrhosis and spontaneous bacterial peritonitis to treatment with intravenous cefotaxime (63 patients) or cefotaxime and intravenous albumin (63 patients). Cefotaxime was given daily in doses that varied according to the serum creatinine level, and albumin was given at a dose of 1.5 g per kilogram of body weight at the time of diagnosis, followed by 1 g per kilogram on day 3. Renal impairment was defined as nonreversible deterioration of renal function during hospitalization. The infection resolved in 59 patients in the cefotaxime group (94 percent) and 62 in the cefotaxime-plus-albumin group (98 percent) (P=0.36). Renal impairment developed in 21 patients in the cefotaxime group (33 percent) and 6 in the cefotaxime-plus-albumin group (10 percent) (P=0.002). Eighteen patients (29 percent) in the cefotaxime group died in the hospital, as compared with 6 (10 percent) in the cefotaxime-plus-albumin group (P=0.01); at three months, the mortality rates were 41 percent (a total of 26 deaths) and 22 percent (a total of 14 deaths), respectively (P=0.03). Patients treated with cefotaxime had higher levels of plasma renin activity than those treated with cefotaxime and albumin; patients with renal impairment had the highest values. In patients with cirrhosis and spontaneous bacterial peritonitis, treatment with intravenous albumin in addition to an antibiotic reduces the incidence of renal impairment and death in comparison with treatment with an antibiotic alone.

1 March 2007 in Journal of Hepatology
Verified
Journal Article
Closed access
MVMaría Varela
María Varela
MRMaría Isabel Real
María Isabel Real
MBMarta Burrel
Marta Burrel
AFAlejandro Forner
Alejandro Forner
MSMargarita Sala
Margarita Sala
JBJordi Bruix
Jordi Bruix

1 January 2000 in Hepatology
Verified
Journal Article
Open access
PDF file
JLJosep M. Llovet
Josep M. Llovet
MSMargarita Sala
Margarita Sala
LCLluís Castells
Lluís Castells
YSYanette Suarez
Yanette Suarez
RVRamon Vilana
Ramon Vilana
JBJordi Bruix
Jordi Bruix
The aim of this randomized controlled trial was to assess the efficacy of interferon alfa-2b (IFN) for the treatment of advanced hepatocellular carcinoma (HCC). Fifty-eight patients with HCC who were not suitable for resection, transplantation, ethanol injection, or arterial embolization were stratified according to their Okuda stage and randomized to receive IFN (3 × 106, 3 times a week, for 1 year) (n = 30) or symptomatic treatment (n = 28). Both groups were identical in terms of age, sex, performance status, presence of constitutional syndrome, Child-Pugh class, Okuda stage, multinodularity, portal thrombosis, and extrahepatic spread. Adhesion to IFN treatment was adequate in 27 patients, with a mean duration of treatment of 8 ± 3 months. However, IFN treatment was associated with side effects in 23 patients, leading to treatment discontinuation in 13 patients. Two of the 30 patients (6.6%) presented a partial response with greater than 50% size reduction and normalization of α-fetoprotein levels. The survival at 1 and 2 years according to intention to treat was not different between the 2 groups (58% and 38% vs. 36% and 12%, respectively, Breslow P = .19, log rank P = .14) and the absence of difference was maintained when dividing patients according to their Okuda stage. The probability of presenting tumor progression (P = .17), or deterioration of Child-Pugh class (P= .37), performance status (P = .07), or Okuda stage (P = .44) was not modified by IFN treatment. These results indicate that IFN is not properly tolerated in patients with cirrhosis and advanced HCC and that its administration prompts no benefit in terms of tumor progression rate and survival.

1 October 1996 in Gastroenterology
Verified
Journal Article
Closed access
MNM Navasa
M Navasa
AFA Follo
A Follo
JLJm Llovet
Jm Llovet
GCG Clemente
G Clemente
VVV Vargas
V Vargas
JRJ Rodes
J Rodes

1 November 2001 in Journal of Hepatology
Verified
Journal Article
Closed access
JCJuan Córdoba
Juan Córdoba
JAJuli Alonso
Juli Alonso
ARAlex Rovira
Alex Rovira
CJCarlos Jacas
Carlos Jacas
FSFrancesc Sanpedro
Francesc Sanpedro
JGJaume Guardia
Jaume Guardia

1 January 2003 in Journal of Hepatology
Verified
Journal Article
Closed access
AMAntoni Mas
Antoni Mas
JRJuan Rodés
Juan Rodés
LSLourdes Sunyer
Lourdes Sunyer
Luis RodrigoLuis Rodrigo
Luis Rodrigo
RPRamon Planas
Ramon Planas
APAlbert Pardo
Albert Pardo